9 Minutes for Colonoscopy Withdrawal

Sponsor
Changhai Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03399045
Collaborator
No.85 Hospital, Changning, Shanghai, China (Other), The Second Clinical Medical College of Jinan University (Other), Qinghai People's Hospital (Other), Shaanxi Provincial People's Hospital (Other), Shanghai 8th People's Hospital (Other), Yantaishan Hospital of Yantai City (Other), First Affiliated Hospital of Harbin Medical University (Other), Changzhi People's Hospital (Other), Ningbo Medical Center Li Huili Eastern Hospital (Other), The Third People's Hospital of Datong (Other), The First Affiliated Hospital of the Medical College, Shihezi University (Other), The First Affiliated Hospital of Dalian Medical University (Other), Seventh Medical Center of PLA Army General Hospital (Other)
1,027
1
2
17.5
58.8

Study Details

Study Description

Brief Summary

A withdrawal time of at least 6 minutes has been considered to be necessary to guarantee the adenoma detection rate and the critical quality criterion of colonoscopy. However, several large observational investigations demonstrated that 9 minutes will be in favor of higher adenoma detection rate and lower risk of interval colorectal cancer, when compared with 6-minute withdrawal. Meanwhile, a few studies also indicated that no significant benefit were observed in longer withdrawal time. Up to now, no randomized controlled trials have been conducted to give a definitive conclusion. Therefore, we performed a multicenter, prospective, randomized Controlled trial to compare adenoma detection rate of 6-minute and 9-minute withdrawal in colonoscopy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: 9-minute withdrawal
  • Procedure: 6-minute withdrawal
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
1027 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Impact of 9-minute Withdrawal Time on Adenoma Detection Rateļ¼ša Multicenter, Prospective, Randomized Controlled Trial
Actual Study Start Date :
Jan 20, 2018
Actual Primary Completion Date :
Jul 1, 2019
Actual Study Completion Date :
Jul 6, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: 9-minute withdrawal group

Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw. A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included in the 9 minutes.

Procedure: 9-minute withdrawal
Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw

Active Comparator: 6-minute withdrawal group

Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw. A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy willwill not be included in the 9 minutes.

Procedure: 6-minute withdrawal
Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw

Outcome Measures

Primary Outcome Measures

  1. adenoma detection rate(ADR) [30mins]

    ADR was calculated adenoma detection rate is the number of patients with at least one adenoma, divided by the total number of patients.

Secondary Outcome Measures

  1. adenomas per colonoscopy(APC) [30mins]

    APC was calculated as the number of adenomas detected during colonoscopy withdraw divided by the number of colonoscopies.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients whose age is between 40-85.

  • Patients who have indications for screening, surveillance and diagnostic colonoscopy.

  • Patients who have signed inform consent form

Exclusion Criteria:
  • Patients who have undergone colonic resection

  • Patients with intracranial and/or central nervous system disease, including cerebral infarction and cerebral hemorrhage.

  • Patients with severe chronic cardiopulmonary and renal disease.

  • Patients who are unwilling or unable to consent.

  • Patients who are not suitable for colonoscopy

  • Patients who received urgent or therapeutic colonoscopy

  • Patients with pregnancy, inflammatory bowel disease, polyposis of colon, colorectal cancer, or intestinal obstruction

  • Patients who are taking aspirin, clopidogrel or other anticoagulants

  • Patients with Aronchick score > 3

Contacts and Locations

Locations

Site City State Country Postal Code
1 Changhai Hospital, Second Military Medical University Shanghai China 200433

Sponsors and Collaborators

  • Changhai Hospital
  • No.85 Hospital, Changning, Shanghai, China
  • The Second Clinical Medical College of Jinan University
  • Qinghai People's Hospital
  • Shaanxi Provincial People's Hospital
  • Shanghai 8th People's Hospital
  • Yantaishan Hospital of Yantai City
  • First Affiliated Hospital of Harbin Medical University
  • Changzhi People's Hospital
  • Ningbo Medical Center Li Huili Eastern Hospital
  • The Third People's Hospital of Datong
  • The First Affiliated Hospital of the Medical College, Shihezi University
  • The First Affiliated Hospital of Dalian Medical University
  • Seventh Medical Center of PLA Army General Hospital

Investigators

  • Principal Investigator: Li Zhaoshen, M.D, Changhai Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zhaoshen Li, Director of Gastroenterology Dept, Changhai Hospital
ClinicalTrials.gov Identifier:
NCT03399045
Other Study ID Numbers:
  • withdrawal time-1
First Posted:
Jan 16, 2018
Last Update Posted:
Jan 2, 2020
Last Verified:
Dec 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 2, 2020